Comparison of clinico-pathological characteristics and survival of recurrent ovarian cancer patients on seven different chemo-protocols

1. B. M. Reid, J. B. Permuth and T. A. Sellers, Epidemiology of ovarian cancer: a review, Cancer Biol. Med. 14 (2017) 9–32; https://doi.org/10.20892/j.issn.2095-3941.2016.008410.20892/j.issn.2095-3941.2016.0084536518728443200Search in Google Scholar

2. J. Permuth-Wey and T. A. Sellers, 20. Epidemiology of Ovarian Cancer, in Cancer Epidemiology: Modifiable Factors (Ed. M. Verma)/Series: Methods of Molecular Biology472 (2009) 413–437, Springer, New York 2009; https://doi.org/10.1007/978-1-60327-492-0_2010.1007/978-1-60327-492-0_2019107446Search in Google Scholar

3. J. Ledermann, F. Raja, C. Fotopoulou, A. Gonzalez-Martin, N. Colombo and C. Sessa (ESMO guidelines working group), Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-up, Ann. Oncol.24 (Suppl. 6) (2013) vi24-vi32. https://doi.org/10.1093/annonc/mdt33310.1093/annonc/mdt33324078660Search in Google Scholar

4. F. Raja, N. Chopra and J. Ledermann, Optimal first-line treatment in ovarian cancer, Ann. Oncol. 23 (Suppl. 10) (2012) x118-x127; https://doi.org/10.1093/annonc/mds31510.1093/annonc/mds31522987945Search in Google Scholar

5. M. Cristea, E. Han, L. Salmon and R. J. Morgan, Review: Practical considerations in ovarian cancer chemotherapy, Ther. Adv. Med. Oncol. 2 (2010) 175–187; https://doi.org/10.1177/175883401036133310.1177/1758834010361333312601621789133Search in Google Scholar

6. M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidi and J. P. Ioannidis, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. Cancer Inst.98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj44310.1093/jnci/djj44317105988Search in Google Scholar

7. M. A. Bookman (Ed.), GOG0182-ICON5: 5-arm phase III randomized trial of paclitaxel (P) and carboplatin (C) vs combinations with gemcitabine (G), PEG-lipososomal doxorubicin (D), or topotecan (T) in patients (pts) with advanced-stage epithelial ovarian (EOC) or primary peritoneal (PPC) carcinoma, J. Clin. Oncol. 24 (Suppl.) (2006) 5002–5002 (ASCO Annual Meeting Proceedings 2006); https://doi.org/10.1200/jco.2006.24.18_suppl.500210.1200/jco.2006.24.18_suppl.5002Search in Google Scholar

8. J. A. Ledermann and R. S. Kristeleit, Optimal treatment for relapsing ovarian cancer, Ann. Oncol. 21 (Suppl. 7) (2010) vii218-222; https://doi.org/10.1093/annonc/mdq37710.1093/annonc/mdq37720943618Search in Google Scholar

9. D. S. Dizon, M. L. Hensley, E. A. Poynor, P. Sabbatini, C. Aghajanian, A. E. Hummer. D. R. Venkatraman and R. Spriggs, Retrospective analysis of carboplatin and paclitaxel as initial second-line therapy for recurrent epithelial ovarian carcinoma: application toward a dynamic disease state model of ovarian cancer, J. Clin. Oncol. 20 (2002) 1238–1247; https://doi.org/10.1200/JCO.2002.20.5.123810.1200/JCO.2002.20.5.123811870166Search in Google Scholar

10. M. U. Rashid, A. Zaidi, D. Torres, F. Sultan, A. Benner, B. Naqvi, A. R. Shakoori, A. Seidel-Renkert, H. Farooq, S. Narod, A. Amin and U. Hamann, Prevalence of BRCA1 and BRCA2 mutations in Pakistani breast and ovarian cancer patients, Int. J. Cancer119 (2006) 2832–2839; https://doi.org/10.1002/ijc.2226910.1002/ijc.2226916998791Search in Google Scholar

11. M. A. Moore, Y. Ariyaratne, F. Badar, Y. Bhurgri, K. Datta, A. Mathew, P. Gangadharan, A. Nandakumar, K. K. Pradhananga, M. H. Talukder, B. B. Yeole and T. Sobue, Cancer epidemiology in South Asia - past, present and future, Asian Pac. J. Cancer Prev. 11 (Suppl. 2) (2010) 49–66.Search in Google Scholar

12. Y. Bhurgri, Karachi cancer registry data - implications for the National Cancer Control Program of Pakistan, Asian Pac. J. Cancer Prev.5 (2004) 77–82.Search in Google Scholar

13. Ovarian cancer second most common type in Pakistan, The Daily News 2016, https://www.the-news.com.pk/print/105779-Ovarian-cancer-second-most-common-type-inPakistan; last access date July 15, 2018.Search in Google Scholar

14. P. Cheema and R. Burkes, Overall survival should be the primary endpoint in clinical trials for advanced non-small-cell lung cancer, Curr. Oncol.20 (2013) e150; https://doi.org/10.3747/co.20.122610.3747/co.20.1226361586623559882Search in Google Scholar

15. E. Eisenhauer, P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij, New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1), Eur. J. Cancer45 (2009) 228–247; https://doi.org/10.1016/j.ejca.2008.10.02610.1016/j.ejca.2008.10.02619097774Search in Google Scholar

16. S. Zhang, F. Liang and I. Tannock, Use and misuse of common terminology criteria for adverse events in cancer clinical trials, BMC Cancer16 (2016) Article ID 392 (6 pages); https://doi.org/10.1186/s12885-016-2408-910.1186/s12885-016-2408-9493272627377548Search in Google Scholar

17. C. Aghajanian, S. V. Blank, B. A. Goff, P. L. Judson, M. G. Teneriello, A. Husain, M. A. Sovak, J. Yi and L. R. Nycum, OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer, J. Clin. Oncol.30 (2012) 2039–2045; https://doi.org/10.1200/JCO.2012.42.050510.1200/JCO.2012.42.0505364632122529265Search in Google Scholar

18. M. Kyrgiou, G. Salanti, N. Pavlidis, E. Paraskevaidis and J. P. Ioannidis, Survival benefits with diverse chemotherapy regimens for ovarian cancer: meta-analysis of multiple treatments, J. Natl. Cancer Inst.98 (2006) 1655–1663; https://doi.org/10.1093/jnci/djj44310.1093/jnci/djj44317105988Search in Google Scholar

19. S. Pignata, G. Scambia, G. Ferrandina, A. Savarese, R. Sorio, E. Breda, V. Gebbia, P. Musso, L. Frigerio, P. Del Medico, A. V. Lombardi, A. Febbraro, P. Scollo, A. Ferro, S. Tamberi, A. Brandes, A. Ravaioli, M. R. Valerio, E. Aitini, D. Natale, L. Scaltriti, S. Greggi, C. Pisano, D. Lorusso, V. Salutari, F. Legge, M. Di Maio, A. Morabito, C. Gallo and F. Perrone, Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial, J. Clin. Oncol.29 (2011) 3628–3635; https://doi.org/10.1200/JCO.2010.33.856610.1200/JCO.2010.33.856621844495Search in Google Scholar

20. R. S. Suidan, C. M. St Clair, S. J. Lee, J. N. Barlin, K. C. Long Roche, E. J. Tanner, Y. Sonoda, R. R. Barakat, O. Zivanovic and D. S. Chi, A comparison of primary intraperitoneal chemotherapy to consolidation intraperitoneal chemotherapy in optimally resected advanced ovarian cancer, Gynecol. Oncol. 134 (2014) 468–472; https://doi.org/10.1016/j.ygyno.2014.07.09010.1016/j.ygyno.2014.07.09025042672Search in Google Scholar

21. M. J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, E. Simonsen, G. Stuart, S. Kaye, I. Vergote, R. B. R. Grimshaw, R. J. Atkinson, K. D. Swenerton, C. Trope, M. Nardi, J. Kaern, S. Tumolo, P. Timmers, J. Roy, F. Lhoas, B. Lindvall, M. Bacon, A. Birt, J. E. Andersen, B. Zee, J. Paul, B. Baron and S. Pecorelli, Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results, J. Natl. Cancer Inst.92 (2000) 699–708; https://doi.org/10.1093/jnci/92.9.69910.1093/jnci/92.9.69910793106Search in Google Scholar

22. A. du Bois, H. J. Lück, W. Meier, H. P. Adams, V. Möbus, S. Costa, T. Bauknecht, B. Richter, M. Warm, W. Schröder, S. Olbricht, U. Nitz, C. Jackisch, G. Emons, U. Wagner, W. Kuhn and J. Pfisterer, A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer, J. Natl. Cancer Inst. 95 (2003) 1320–1329; doi 10.1093/jnci/djg03610.1093/jnci/djg03612953086Search in Google Scholar

23. R. F. Ozols, B. N. Bundy, B. E. Greer, J. M. Fowler, D. Clarke-Pearson, R. A. Burger, R. S. Mannel, K. DeGeest, E. M. Hartenbach and R. Baergen, Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study, J. Clin. Oncol.21 (2003) 3194–3200; https://doi.org/10.1200/jco.2003.02.15310.1200/JCO.2003.02.15312860964Search in Google Scholar

24. M. Fung-Kee-Fung, T. Oliver, L. Elit, A. Oza, H. W. Hirte and P. Bryson, Optimal chemotherapy treatment for women with recurrent ovarian cancer, Curr. Oncol.14 (2007) 195–208.10.3747/co.2007.148Search in Google Scholar

25. Y. Wang, J. Herrstedt, H. Havsteen, R. DePoint Christensen, M. R. Mirza, B. Lund, J. Maenpaa and G. Kristensen, A multicenter, non-randomized, phase II study of docetaxel and carboplatin administered every 3 weeks as second line chemotherapy in patients with first relapse of platinum sensitive epithelial ovarian, peritoneal or fallopian tube cancer, BMC Cancer14 (2014) Article ID 937 (7 pages); https://doi.org/10.1186/1471-2407-14-93710.1186/1471-2407-14-937Search in Google Scholar

26. L. A. Holmberg, P. Paley and B. Goff, Docetaxel and carboplatin as salvage therapy for first-relapsed, platinum-sensitive, stage III/IV advanced ovarian cancer, Clin. Ovar. Other Gynecol. Cancer7 (2014) 13–17; https://doi.org/10.1016/j.cogc.2014.12.00510.1016/j.cogc.2014.12.005Search in Google Scholar

27. J. M. Gibson, S. Alzghari, C. Ahn, H. Trantham and N. M. La-Beck, The role of pegylated liposomal doxorubicin in ovarian cancer: a meta-analysis of randomized clinical trials, Oncologist18 (2013) 1022–1031; https://doi.org/10.1634/theoncologist.2013-012610.1634/theoncologist.2013-0126Search in Google Scholar

28. M. Parmar, J. Ledermann, N. Colombo, A. du Bois, J. F. Delaloye, G. B. Kristensen, S. Wheeler, A. M. Swart, W. Qian, V. Torri, I. Floriani, G. Jayson and A. Lamont, C. Tropé, Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial, Lancet361 (2003) 2099–2106; https://doi.org/10.1016/S0140-6736(03)13718-X10.1016/S0140-6736(03)13718-XSearch in Google Scholar

29. J. Pfisterer, M. Plante, I. Vergote, A. du Bois, H. Hirte, A. J. Lacave, U. Wagner, A. Stähle, G. Stuart, R. Kimmig, S. Olbricht, T. Le, J. Emerich, W. Kuhn, J. Bentley, C. Jackisch, H. J. Lück, J. Rochon, A. H. Zimmermann and E. Eisenhauer, Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG, J. Clin. Oncol.24 (2006) 4699–4707; https://doi.org/10.1200/JCO.2006.06.091310.1200/JCO.2006.06.091316966687Search in Google Scholar

30. D. Bafaloukos, H. Linardou, G. Aravantinos, C. Papadimitriou, A. Bamias, G. Fountzilas, H. P. Kalofonos, P. Kosmidis, E. Timotheadou, T. Makatsoris, E. Samantas, E. Briasoulis, C. Christodoulou, P. Papakostas, D. Pectasides and A. M. Dimopoulos, A randomized phase II study of carboplatin plus pegylated liposomal doxorubicin versus carboplatin plus paclitaxel in platinum sensitive ovarian cancer patients: a Hellenic Cooperative Oncology Group study, BMC Med.8 (2010) Article ID 3 (12 pages); https://doi.org/10.1186/1741-7015-8-310.1186/1741-7015-8-3282365320055981Search in Google Scholar

31. C. J. Dunton, Management of treatment-related toxicity in advanced ovarian cancer, Oncologist7 (Suppl. 5) (2002) 11–19.10.1634/theoncologist.7-suppl_5-1112324629Search in Google Scholar

32. K. Kudoh, M. Takano, H. Kouta, R. Kikuchi, T. Kita, M. Miyamoto, A. Watanabe, M. Kato, T. Goto and Y. Kikuchi, Effects of bevacizumab and pegylated liposomal doxorubicin for the patients with recurrent or refractory ovarian cancers, Gynecol. Oncol.122 (2011) 233–237; https://doi.org/10.1016/j.ygyno.2011.04.04610.1016/j.ygyno.2011.04.04621601912Search in Google Scholar